Literature DB >> 21436579

The adaptive stroma joining the antiangiogenic resistance front.

Oriol Casanovas1.   

Abstract

Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21436579      PMCID： PMC3069791          DOI： 10.1172/JCI46430

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  19 in total

Review 1.  Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Authors:  R S Kerbel; J Yu; J Tran; S Man; A Viloria-Petit; G Klement; B L Coomber; J Rak
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

2.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

3.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Authors:  Tina Cascone; Matthew H Herynk; Li Xu; Zhiqiang Du; Humam Kadara; Monique B Nilsson; Carol J Oborn; Yun-Yong Park; Baruch Erez; Jörg J Jacoby; Ju-Seog Lee; Heather Y Lin; Fortunato Ciardiello; Roy S Herbst; Robert R Langley; John V Heymach
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

4.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

Review 5.  Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.

Authors:  Yongping Crawford; Napoleone Ferrara
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

6.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Authors:  Iris Helfrich; Inka Scheffrahn; Sönke Bartling; Joachim Weis; Verena von Felbert; Mark Middleton; Masahi Kato; Süleyman Ergün; Helmut G Augustin; Dirk Schadendorf
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

7.  Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

Authors:  Barbara Sennino; Frank Kuhnert; Sebastien P Tabruyn; Michael R Mancuso; Dana D Hu-Lowe; Calvin J Kuo; Donald M McDonald
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

Review 8.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

9.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Authors:  Farbod Shojaei; Xiumin Wu; Ajay K Malik; Cuiling Zhong; Megan E Baldwin; Stefanie Schanz; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

Review 10.  Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531
View more
  5 in total

1.  The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Authors:  Tina Cascone; Li Xu; Heather Y Lin; Wenbin Liu; Hai T Tran; Yuan Liu; Kathryn Howells; Vincent Haddad; Emer Hanrahan; Monique B Nilsson; Maria A Cortez; Uma Giri; Humam Kadara; Babita Saigal; Yun-Yong Park; Weiyi Peng; Ju-Seog Lee; Anderson J Ryan; Juliane M Jüergensmeier; Roy S Herbst; Jing Wang; Robert R Langley; Ignacio I Wistuba; Jack J Lee; John V Heymach
Journal:  Clin Cancer Res       Date:  2017-05-30       Impact factor: 12.531

2.  Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice.

Authors:  Hanseul Yang; Sungsu Lee; Seungjoo Lee; Kangsan Kim; Yeseul Yang; Jeong Hoon Kim; Ralf H Adams; James M Wells; Sean J Morrison; Gou Young Koh; Injune Kim
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

3.  Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Authors:  Qingyu Zhou; Hua Lv; Amin R Mazloom; Huilei Xu; Avi Ma'ayan; James M Gallo
Journal:  J Pharmacol Exp Ther       Date:  2012-08-06       Impact factor: 4.030

4.  Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Authors:  Satish Sharan; Sukyung Woo
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

Review 5.  Angiocrine endothelium: from physiology to cancer.

Authors:  Jennifer Pasquier; Pegah Ghiabi; Lotfi Chouchane; Kais Razzouk; Shahin Rafii; Arash Rafii
Journal:  J Transl Med       Date:  2020-02-03       Impact factor: 5.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.